Cover Image

Vernakalant

In September 2010, vernakalant (Brinavess; Cardiome/Merck) was granted marketing authorization by the European Commission for the rapid conversion of recent-onset atrial fibrillation to sinus rhythm.

Saved in:
Bibliographic Details
Main Authors: Dobrev, Dobromir (Author) , Hamad, Bashar (Author) , Kirkpatrick, Peter (Author)
Format: Article (Journal)
Language:English
Published: 01 December 2010
In: Nature reviews. Drug discovery
Year: 2010, Volume: 9, Issue: 12, Pages: 915-916
ISSN:1474-1784
DOI:10.1038/nrd3323
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/nrd3323
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/nrd3323
Get full text
Author Notes:Dobromir Dobrev, Bashar Hamad and Peter Kirkpatrick
Description
Summary:In September 2010, vernakalant (Brinavess; Cardiome/Merck) was granted marketing authorization by the European Commission for the rapid conversion of recent-onset atrial fibrillation to sinus rhythm.
Item Description:Gesehen am 08.05.2023
Physical Description:Online Resource
ISSN:1474-1784
DOI:10.1038/nrd3323

Similar Items